Global Human Rabies Immunoglobulin (IM) market is forecast to 510 million US in 2025
In 2017, the global Human Rabies Immunoglobulin (IM) market size was 290 million US$ and is forecast to 510 million US in 2025, growing at a CAGR of 7.6% from 2018. https://www.qyresearch.com/index/detail/736723/global-human-rabies-immunoglobulin-im-market
In 2017, the global Human Rabies Immunoglobulin (IM) market size was 290 million US$ and is forecast to 510 million US in 2025, growing at a CAGR of 7.6% from 2018.
https://www.qyresearch.com/index/detail/736723/global-human-rabies-immunoglobulin-im-market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Global</strong> <strong>Human</strong> <strong>Rabies</strong><br />
<strong>Immunoglobul<strong>in</strong></strong> (<strong>IM</strong>) <strong>market</strong> <strong>is</strong><br />
<strong>forecast</strong> <strong>to</strong> <strong>510</strong> <strong>million</strong> <strong>US</strong> <strong>in</strong> <strong>2025</strong><br />
QYRESEARCH FOC<strong>US</strong> ON MARKET SURVEY ANDRESEARCH<br />
www.qyresearch.com
Beij<strong>in</strong>g Hengzhou Bozhi International<br />
Information Consult<strong>in</strong>g<br />
Web: www.qyresearch.com<br />
TEL:+86-13660489419, Office:+86-2022093278<br />
Media: press@qyresearch.com<br />
Market<strong>in</strong>g: sales@qyresearchglobal.com<br />
Facebook: @QYResearchOfficial,<br />
Twitter: @QYResearch_<br />
Wechat Official Account: QYResearch, Weibo: 恒 州 博 智<br />
www.qyresearch.com
QYResearch<br />
• <strong>Rabies</strong> immunoglobul<strong>in</strong> (RIG) <strong>is</strong> a medication made up of antibodies<br />
aga<strong>in</strong>st the rabies virus. It <strong>is</strong> used <strong>to</strong> prevent rabies follow<strong>in</strong>g exposure.<br />
• Figure <strong>Human</strong> <strong>Rabies</strong> <strong>Immunoglobul<strong>in</strong></strong> (<strong>IM</strong>) <strong>is</strong> rabies immunoglobul<strong>in</strong><br />
antibody by the high price of healthy human plasma prote<strong>in</strong> low<br />
temperature ethanol separation or other separation methods approved<br />
separation and purification, and by virus removal and <strong>in</strong>activation<br />
treatment <strong>is</strong> made. Ma<strong>in</strong>ly used for rabies or other crazy animal bites,<br />
scratches patient's passive immunization.<br />
www.qyresearch.com
QYResearch<br />
• The classification accord<strong>in</strong>g <strong>to</strong> the material of <strong>Human</strong> <strong>Rabies</strong><br />
<strong>Immunoglobul<strong>in</strong></strong> (<strong>IM</strong>) <strong>in</strong>cludes ERIG, HRIG, and the<br />
proportion of HRIG <strong>in</strong> 2017<strong>is</strong> about 86.7%, and the<br />
proportion <strong>is</strong> <strong>in</strong> <strong>in</strong>creas<strong>in</strong>g trend from 2013 <strong>to</strong> 2017.<br />
• For ERIGs, the dosage <strong>is</strong> 40 IU per kg body weight subject<br />
<strong>to</strong> a maximum of 3000 IU. For HRIGs, the dosage <strong>is</strong> 20 IU<br />
per kg body weight subject <strong>to</strong> a maximum of 1500 IU.<br />
www.qyresearch.com
QYResearch<br />
<strong>Human</strong> <strong>Rabies</strong> <strong>Immunoglobul<strong>in</strong></strong> (<strong>IM</strong>) <strong>is</strong> widely used for<br />
the Category II Exposure and Category III Exposure,<br />
the most proportion of <strong>Human</strong> <strong>Rabies</strong> <strong>Immunoglobul<strong>in</strong></strong><br />
(<strong>IM</strong>) <strong>is</strong> used for Category III Exposure, and the<br />
proportion <strong>in</strong> 2017 <strong>is</strong> about 82.6%.<br />
Ch<strong>in</strong>a <strong>is</strong> the largest sales place, with a sales <strong>market</strong><br />
share nearly 61.4% <strong>in</strong> 2017, because of the population.<br />
North America enjoys 4.3% <strong>market</strong> share.<br />
www.qyresearch.com<br />
www.qyresearch.com
QYResearch<br />
In 2017, the global <strong>Human</strong> <strong>Rabies</strong> <strong>Immunoglobul<strong>in</strong></strong> (<strong>IM</strong>) <strong>market</strong><br />
size was 290 <strong>million</strong> <strong>US</strong>$ and <strong>is</strong> <strong>forecast</strong> <strong>to</strong> <strong>510</strong> <strong>million</strong> <strong>US</strong> <strong>in</strong><br />
<strong>2025</strong>, grow<strong>in</strong>g at a CAGR of 7.6% from 2018. The objectives<br />
of th<strong>is</strong> study are <strong>to</strong> def<strong>in</strong>e, segment, and project the size of<br />
the <strong>Human</strong> <strong>Rabies</strong> <strong>Immunoglobul<strong>in</strong></strong> (<strong>IM</strong>) <strong>market</strong> based on<br />
company, product type, application and key regions.<br />
Click <strong>to</strong> view the full report:<br />
https://www.qyresearch.com/<strong>in</strong>dex/detail/736723/globalhuman-rabies-immunoglobul<strong>in</strong>-im-<strong>market</strong><br />
www.qyresearch.com<br />
www.qyresearch.com
Change language